{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:12:49Z","timestamp":1794867169311,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a need for more effective treatments for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Nerandomilast (BI 1015550), an oral preferential inhibitor of phosphodiesterase 4B, is being evaluated in two randomized Phase III trials: FIBRONEER\u2122-IPF (NCT05321069) and FIBRONEER\u2122-ILD (NCT05321082). FIBRONEER\u2122-ON is an open-label extension (OLE) of these studies that will evaluate the long-term safety and efficacy of nerandomilast. Here, we describe the study design of the OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective 98-week OLE will follow the Phase III parent trials, which are currently underway with 1177 patients enrolled in FIBRONEER\u2122-IPF and 1178 patients enrolled in FIBRONEER\u2122-ILD. Approximately 1700 patients from 44 countries are expected to complete the parent trials and will be eligible for continuing into the OLE; this estimate assumes that there will be a discontinuation rate of ~25% over the duration of the parent trials and &gt;\u200990% of eligible patients will agree to participate in the OLE. Irrespective of whether previously on active treatment or placebo, all patients in the OLE will be treated with nerandomilast at either 9\u00a0mg or 18\u00a0mg twice daily, depending on which dose demonstrates the most favorable benefit\u2013risk profile in the parent trials. The primary endpoint will be the occurrence of any adverse event over the course of the OLE. This trial will also monitor long-term efficacy outcomes, including forced vital capacity change, and time to first exacerbation, disease progression, hospitalization and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will provide information on the long-term safety, tolerability and efficacy of nerandomilast in patients with IPF and PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>FIBRONEER\u2122-ON: ClinicalTrials.gov: NCT06238622, registered 2 February 2024. Protocol version and date: version 3.0, 29 Apr 2024. FIBRONEER\u2122-IPF: ClinicalTrials.gov: NCT05321069, registered 11 March 2022.FIBRONEER\u2122-ILD: ClinicalTrials.gov: NCT05321082, registered 11 March 2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-025-03973-7","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:48:38Z","timestamp":1764848918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis\u00a0(FIBRONEER\u2122-ON)"],"prefix":"10.1186","volume":"26","author":[{"given":"Wim A.","family":"Wuyts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Kanakapura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Drzewuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Coeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"10","key":"3973_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958\u201368.","journal-title":"N Engl J Med"},{"key":"3973_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743977","volume":"8","author":"CR Copeland","year":"2021","unstructured":"Copeland CR, Lancaster LH. Management of progressive fibrosing interstitial lung diseases (PF-ILD). Front Med (Lausanne). 2021;8:743977.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"3973_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"151","key":"3973_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"3973_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"3973_CR6","unstructured":"OFEV\u00ae (nintedanib). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/205832Orig1s016lbl.pdf"},{"key":"3973_CR7","unstructured":"Ofev\u00ae (nintedanib). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf"},{"key":"3973_CR8","unstructured":"ESBRIET\u00ae (pirfenidone). Prescribing information.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022535s012,208780s002lbl.pdf"},{"key":"3973_CR9","unstructured":"Esbriet\u00ae (pirfenidone). Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002154\/WC500103049.pdf"},{"issue":"1","key":"3973_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001580","volume":"10","author":"TM Maher","year":"2023","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A-M, Kreuter M, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023;10(1):e001580.","journal-title":"BMJ Open Respir Res"},{"key":"3973_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3973_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","volume":"28","author":"C Valenzuela","year":"2022","unstructured":"Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med. 2022;28(5):407\u201313.","journal-title":"Curr Opin Pulm Med"},{"key":"3973_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106626","volume":"189","author":"T Goos","year":"2021","unstructured":"Goos T, De Sadeleer LJ, Yserbyt J, De Langhe E, Dubbeldam A, Verbeken EK, et al. Defining and predicting progression in non-IPF interstitial lung disease. Respir Med. 2021;189:106626.","journal-title":"Respir Med"},{"issue":"10","key":"3973_CR14","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/rheumatology\/kev121","volume":"54","author":"HM Kwon","year":"2015","unstructured":"Kwon HM, Kang EH, Park JK, Go DJ, Lee EY, Song YW, et al. A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2015;54(10):1792\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"3973_CR15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SL, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases [Supplementary Appendix]. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"3973_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"key":"3973_CR17","unstructured":"ACTEMRA\u00ae (tocilizumab). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125276s131lbl.pdf"},{"issue":"3","key":"3973_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/mr\/roac055","volume":"33","author":"Y Narita","year":"2023","unstructured":"Narita Y, Funatogawa T, Mii K, Adachi H, Tamura A, Yamakido S. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. Mod Rheumatol. 2023;33(3):525\u201332.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"3973_CR19","doi-asserted-by":"publisher","first-page":"00240","DOI":"10.1183\/23120541.00240-2022","volume":"8","author":"TM Maher","year":"2022","unstructured":"Maher TM, Schlecker C, Luedtke D, Bossert S, Zoz DF, Schultz A. Phase I studies of BI 1015550, a preferential PDE4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2022;8(4):00240\u20132022.","journal-title":"ERJ Open Res"},{"issue":"1","key":"3973_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001563","volume":"10","author":"L Richeldi","year":"2023","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Respir Res. 2023;10(1):e001563.","journal-title":"BMJ Open Respir Res"},{"issue":"15","key":"3973_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154964","volume":"27","author":"L Crocetti","year":"2022","unstructured":"Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules. 2022;27(15):4964.","journal-title":"Molecules"},{"issue":"23","key":"3973_CR22","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM, Trial I. Trial of a Preferential phosphodiesterase 4b inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386(23):2178\u201387.","journal-title":"N Engl J Med"},{"key":"3973_CR23","unstructured":"NCT05321082. A study to find out whether BI 1015550 improves lung function in people with progressive fibrosing interstitial lung diseases (PF-ILDs).\u00a0https:\/\/clinicaltrials.gov\/study\/NCT05321082"},{"key":"3973_CR24","unstructured":"A study to find out whether BI 1015550 improves lung function in people with idiopathic pulmonary fibrosis (IPF) (NCT05321069).\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05321069"},{"issue":"3","key":"3973_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3973_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2024.100729","volume":"47","author":"K Bartold","year":"2024","unstructured":"Bartold K, Iskierko Z, Sharma PS, Lin HY, Kutner W. Idiopathic pulmonary fibrosis (IPF): diagnostic routes using novel biomarkers. Biomed J. 2024;47(4):100729.","journal-title":"Biomed J"},{"issue":"1","key":"3973_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01801-0","volume":"22","author":"H Jessen","year":"2021","unstructured":"Jessen H, Hoyer N, Prior TS, Frederiksen P, Karsdal MA, Leeming DJ, et al. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):205.","journal-title":"Respir Res"},{"issue":"3","key":"3973_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00408-017-9993-5","volume":"195","author":"J Guiot","year":"2017","unstructured":"Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017;195(3):273\u201380.","journal-title":"Lung"},{"issue":"18","key":"3973_CR29","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"23","key":"3973_CR30","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209\u201319.","journal-title":"N Engl J Med"},{"key":"3973_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.rmed.2017.07.010","volume":"130","author":"C Johnson","year":"2017","unstructured":"Johnson C, Rosen P, Lloyd T, Horton M, Christopher-Stine L, Oddis CV, et al. Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respir Med. 2017;130:52\u20134.","journal-title":"Respir Med"},{"issue":"suppl 67","key":"3973_CR32","first-page":"OA854","volume":"62","author":"R Santos","year":"2023","unstructured":"Santos R, Gouveia Cardoso C, Caetano Mota P, Coelho D, Gon\u00e7alves M, Coelho A, Sokhatska O, Beltr\u00e3o M, Guimar\u00e3es S, Souto Moura C, et al. Unveiling common molecular pathways linked to ILDs with progressive fibrosing phenotype: the role of MUC5B promoter variants. Eur Respir J. 2023;62(suppl 67):OA854.","journal-title":"Eur Respir J"},{"issue":"4","key":"3973_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1164\/rccm.202401-0238SO","volume":"210","author":"A Adegunsoye","year":"2024","unstructured":"Adegunsoye A, Kropski JA, Behr J, Blackwell TS, Corte TJ, Cottin V, et al. Genetics and genomics of pulmonary fibrosis: charting the molecular landscape and shaping precision medicine. Am J Respir Crit Care Med. 2024;210(4):401\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"150","key":"3973_CR34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018","volume":"27","author":"JJ Swigris","year":"2018","unstructured":"Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, et al. Patients\u2019 perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180075.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"3973_CR35","doi-asserted-by":"publisher","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","volume":"7","author":"J Swigris","year":"2021","unstructured":"Swigris J, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The living with pulmonary fibrosis questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res. 2021;7(2):00145\u20132020.","journal-title":"ERJ Open Res"},{"issue":"2","key":"3973_CR36","doi-asserted-by":"publisher","first-page":"00681","DOI":"10.1183\/23120541.00681-2021","volume":"8","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O\u2019Brien EC, et al. Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures. ERJ Open Res. 2022;8(2):00681\u20132021.","journal-title":"ERJ Open Res"},{"issue":"7","key":"3973_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","volume":"57","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57(7):1253\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3973_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","volume":"11","author":"M Cazzola","year":"2016","unstructured":"Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016;11(7):733\u201344.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"3973_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1901-3","volume":"21","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1\u20133 pooled analysis. Arthritis Res Ther. 2019;21(1):118.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3973_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/toxsci\/kfm161","volume":"100","author":"N Dagues","year":"2007","unstructured":"Dagues N, Pawlowski V, Sobry C, Hanton G, Borde F, Soler S, et al. Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol Sci. 2007;100(1):238\u201347.","journal-title":"Toxicol Sci"},{"key":"3973_CR41","unstructured":"DALIRESP\u00ae (roflumilast). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf"},{"issue":"167","key":"3973_CR42","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb M, Crestani B, Maher TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev. 2023;32(167):220206.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"3973_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3973_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031209","volume":"23","author":"MA Schick","year":"2022","unstructured":"Schick MA, Schlegel N. Clinical implication of phosphodiesterase-4-inhibition. Int J Mol Sci. 2022;23(3):1209.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3973_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMoa1803583","volume":"379","author":"RJ Fox","year":"2018","unstructured":"Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846\u201355.","journal-title":"N Engl J Med"},{"issue":"9","key":"3973_CR46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","volume":"42","author":"EL Matteson","year":"2023","unstructured":"Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol. 2023;42(9):2311\u20139.","journal-title":"Clin Rheumatol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03973-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:25:34Z","timestamp":1768472734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-025-03973-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3973"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03973-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This OLE will be carried out in compliance with the protocol, the ethical principles laid down in the Declaration of Helsinki, in accordance with the International Council for Harmonization (ICH) Guidelines for Good Clinical Practice (GCP), the European Union (EU) directive 2001\/20\/European Commission\/EU regulation 536\/2014, the Japanese GCP regulations, and other relevant regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"WW has received fees for advisory boards from Alentis Therapeutics, Boehringer Ingelheim, BMS, Sanofi, and Pliant; received fees as a paid consultant from Alentis Therapeutics, Boehringer Ingelheim, BMS, Sanofi, and Pliant; and has received funding from Alentis Therapeutics, Boehringer Ingelheim and Sanofi. All payments were paid to his institution. LR has received consultancy fees from Chiesi Farmaceutici, CSL Behring, Bristol Myers Squibb, Veracyte, DevPro, GlaxoSmithKline, Gilead, and Biogen; speaker fees from CSL Behring and Bristol Myers Squibb; and advisory fees for Roche, Avalyn Pharma, and Pliant Therapeutics. SA has received research grants from Boehringer Ingelheim and Janssen; and consultancy fees from Boehringer Ingelheim, Novartis, AbbVie, CSL Behring, and AstraZeneca. AA has received research grants and speaker fees from Boehringer Ingelheim and Taiho Pharm. Co.; and has been an advisory committee member for Boehringer Ingelheim, Taiho Pharm. Co., Toray Co. and Kyorin Pharm. Co. VC has received unrestricted grants from Boehringer Ingelheim; consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene\/BMS, CSL Behring, Ferrer, Galapagos, Pliant Therapeutics, PureTech, RedX, Roche, Sanofi, and Shionogi; lecture fees from Boehringer Ingelheim and Roche; support for attending meetings from Boehringer Ingelheim and Roche; has participated in data and safety monitoring boards for Galapagos, Galecto, and Roche; and has been on an adjudication committee for FibroGen. AMHV has received speaker fees from Boehringer Ingelheim, Janssen, Medscape, Merck Sharp & Dohme, Novartis, and Roche; consultancy fees from AbbVie, ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp & Dohme, Pliant Therapeutics, Roche, and Werfen; and grant\/research support from Boehringer Ingelheim and Janssen. MK is an advisor or review panel member for Boehringer Ingelheim, Galapagos, and Roche; and has received consultancy fees, grants, and speaker fees from Boehringer Ingelheim and Roche. JMO has received consultancy fees and grants from Boehringer Ingelheim; and consultancy fees from Roche\/Genentech and Lupin Pharmaceuticals. FJM has served on a steering committee, advisory board, data safety monitoring board, or adjudication committee for Afferent\/Merck, Bayer, Biogen, Boehringer Ingelheim, DevPro, Nitto, Novartis, Respivant, Roche, and Veracyte; and has received consulting fees or payment for presentations from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Bridge Biotherapeutics, CSL Behring, DevPro, IQVIA, Lung Therapeutics, Roche\/Genentech, Sanofi, Shionogi, twoXAR, United Therapeutics, and Veracyte. CV has received personal fees from Boehringer Ingelheim, Roche, and Bristol Myers Squibb; and support for attending meetings from Boehringer Ingelheim and Roche. MSW has received grants from AstraZeneca-Daiichi, Boehringer Ingelheim, Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, and The Dutch Pulmonary Society; consulting fees from Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galecto, Respivant, NeRRe Therapeutics, Horizon Therapeutics, PureTech Health, Kinevant Sciences, Molecure, CSL Behring, Thyron, and Vicore; speaker fees from Boehringer Ingelheim, Galapagos, Roche, Novartis, and CSL Behring; support for attending meetings from Boehringer Ingelheim, Galapagos, and Roche; has participated in advisory boards for Savara, Galapagos, and Dutch lung fibrosis and sarcoidosis patient associations (unpaid). All grants and fees were paid to her institution. AJ is a paid consultant for Elderbrook Solutions GmbH, contracted by Boehringer Ingelheim, and a paid consultant for AbbVie. MK, CC, CD, and GW are employees of Boehringer Ingelheim. TMM has received speaker fees from Boehringer Ingelheim and Roche\/Genentech; and worked as a paid consultant for Boehringer Ingelheim, Roche\/Genentech, AstraZeneca, Bayer, Blade Therapeutics, Bristol Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant Therapeutics, Respivant, Theravance, and Veracyte.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}